DCT

1:24-cv-00815

Vanda Pharma Inc v. MSN Pharma Inc

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:24-cv-00815, D. Del., 06/16/2025
  • Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendant MSN Pharmaceuticals Inc. is a Delaware corporation and has previously consented to venue in the district. Venue is alleged to be proper for Defendant MSN Laboratories Private Limited, an Indian company, on the basis that it may be sued in any judicial district and has also previously consented to venue.
  • Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's Hetlioz LQ® (tasimelteon) oral suspension constitutes an act of infringement of ten U.S. patents.
  • Technical Context: The technology involves methods of using and formulating tasimelteon, a melatonin-receptor agonist, for treating sleep disturbances associated with rare diseases and circadian rhythm disorders.
  • Key Procedural History: This is a Hatch-Waxman action initiated in response to Defendants' ANDA filing and Paragraph IV certification letters. The complaint notes that Defendants have alleged in their notice letters that certain patents are invalid as anticipated by a Chinese patent application, a position Plaintiff contests by arguing the prior art reference is not enabled.

Case Timeline

Date Event
2012-01-26 Priority Date for '510, '770, '129, '229, and '556 Patents
2014-02-12 Priority Date for '977 and '011 Patents
2014-09-02 Priority Date for '119 and '622 Patents
2018-09-11 U.S. Patent No. 10,071,977 Issues
2019-01-15 U.S. Patent No. 10,179,119 Issues
2019-12-13 Priority Date for '446 Patent
2020-04-07 U.S. Patent No. 10,610,510 Issues
2020-12-01 FDA approves Hetlioz® capsules for Smith-Magenis Syndrome (SMS)
2020-12-01 FDA approves Hetlioz LQ® oral suspension
2021-04-20 U.S. Patent No. 10,980,770 Issues
2022-03-08 U.S. Patent No. 11,266,622 Issues
2022-03-29 U.S. Patent No. 11,285,129 Issues
2023-01-31 U.S. Patent No. 11,566,011 Issues
2023-09-19 U.S. Patent No. 11,759,446 Issues
2023-12-26 U.S. Patent No. 11,850,229 Issues
2024-03-05 U.S. Patent No. 11,918,556 Issues
2024-06-03 Plaintiff receives "First Notice Letter" from Defendants regarding ANDA filing
2025-03-19 Plaintiff receives "Second Notice Letter" from Defendants
2025-06-16 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,179,119 - "Method of Treatment", issued January 15, 2019

The Invention Explained

  • Problem Addressed: The patent addresses the severe and chronically disrupted sleep patterns experienced by individuals with Smith-Magenis Syndrome (SMS), a rare genetic disorder. A contributing factor is an "inverse" circadian pattern of melatonin, where melatonin is high during the day and low at night, the opposite of the normal pattern '119 Patent, col. 1:13-43
  • The Patented Solution: The invention is a method of treating these sleep disturbances by administering an "effective amount" of tasimelteon, a melatonin agonist, once daily before bedtime. This aims to regulate the sleep/wake cycle in SMS patients '119 Patent, abstract '119 Patent, col. 2:7-14 The patent's figures graphically depict melatonin and cortisol levels in an SMS patient over several days, illustrating the underlying disordered circadian rhythm the invention seeks to treat '119 Patent, FIGS. 4-6
  • Technical Importance: The invention provides a specific pharmacological intervention for a debilitating symptom of a rare disease for which no effective treatment was previously available (Compl. ¶¶11; Compl. ¶13).

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶98
  • Claim 1 requires:
    • A method for the treatment of a sleep disorder in a patient with Smith-Magenis Syndrome (SMS), the method comprising:
    • internally administering to the patient an effective amount of tasimelteon
    • once daily before bedtime.

U.S. Patent No. 11,266,622 - "Method of Treatment", issued March 8, 2022

The Invention Explained

  • Problem Addressed: Similar to the '119 patent, the '622 patent addresses sleep disturbances in patients with SMS, which are associated with an abnormal melatonin secretion pattern '622 Patent, col. 1:13-43
  • The Patented Solution: The invention provides a method for treating sleep disorders in SMS patients by administering a specific dose of 20 mg of tasimelteon daily. This method moves beyond the broader "effective amount" to a specific, clinically evaluated dosage '622 Patent, claim 1 '622 Patent, col. 6:4-7
  • Technical Importance: This patent refines the treatment method by specifying a precise dosage (20 mg), providing clearer guidance for clinical application compared to the more general "effective amount" described in prior art Compl. ¶34

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶108
  • Claim 1 requires:
    • A method for the treatment of a sleep disorder in a patient with Smith-Magenis Syndrome (SMS), the method comprising:
    • administering to the patient 20 mg of tasimelteon daily.

Multi-Patent Capsule: The Beta Blocker Interaction Patents (U.S. Patent Nos. 11,285,129; 11,850,229; and 11,918,556)

  • Technology Synopsis: These patents address the negative interaction between tasimelteon and beta-adrenergic receptor antagonists ("beta blockers"). The patents describe Vanda's discovery that patients taking beta blockers were less likely to respond to tasimelteon therapy Compl. ¶49 The inventions cover methods of administering tasimelteon that involve identifying and managing a patient's use of beta blockers to avoid this reduced efficacy Compl. ¶48
  • Asserted Claims: At least claim 1 of each patent is asserted Compl. ¶118 Compl. ¶128 Compl. ¶177
  • Accused Features: Plaintiff alleges that Defendants' proposed product label, by copying the Hetlioz® label, will instruct prescribers to determine whether a patient is taking a beta blocker and to have the patient cease or discontinue its use before administering the accused product, thereby inducing infringement Compl. ¶¶52-54

Multi-Patent Capsule: The Smoker Method of Treatment Patents (U.S. Patent Nos. 10,610,510 and 10,980,770)

  • Technology Synopsis: These patents address the harmful impact of smoking and co-administration with CYP1A2 inhibitors on the metabolism of tasimelteon Compl. ¶62 Vanda's clinical studies allegedly showed that these factors affect patient exposure to the drug Compl. ¶63 The patents claim methods of treatment that avoid these harmful effects Compl. ¶62
  • Asserted Claims: At least claim 1 of each patent is asserted Compl. ¶138 Compl. ¶148
  • Accused Features: Plaintiff alleges that Defendants' proposed product label will instruct prescribers to determine if a patient is a smoker or is taking a CYP1A2 inhibitor, and to counsel the patient to cease or discontinue such activities before using the accused product, allegedly inducing infringement Compl. ¶¶67-68

Multi-Patent Capsule: Suspension SMS Method of Treatment Patent (U.S. Patent No. 11,759,446)

  • Technology Synopsis: This patent relates to methods of treating SMS using tasimelteon in a liquid dosage form, with specific dosage amounts based on patient weight Compl. ¶75 The patent also discloses characteristics of a liquid tasimelteon formulation and dosing considerations for treating SMS Compl. ¶76
  • Asserted Claims: At least claim 1 is asserted Compl. ¶158
  • Accused Features: Defendants' ANDA product is a liquid suspension. Plaintiff alleges the proposed label will instruct administration in different dosage amounts depending on patient weight and instruct caregivers to shake the liquid before administration, thereby inducing infringement of the claimed method Compl. ¶¶79-81

Multi-Patent Capsule: The High Purity Tasimelteon Patents (U.S. Patent Nos. 10,071,977 and 11,566,011)

  • Technology Synopsis: These patents claim highly purified tasimelteon active pharmaceutical ingredient (API) and pharmaceutical compositions containing it. The claims are defined by specific upper limits for certain named impurities (Impurities 1-7) Compl. ¶88
  • Asserted Claims: At least claim 24 of the '977 patent and claim 4 of the '011 patent are asserted Compl. ¶168 Compl. ¶173
  • Accused Features: Plaintiff alleges on information and belief that Defendants' ANDA Product is a pharmaceutical composition comprised of purified tasimelteon API that meets the claimed purity profile (i.e., does not contain any of Impurities 1-7 at a concentration greater than about 0.15%) and therefore will directly infringe Compl. ¶¶89-91

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is Defendants' proposed generic tasimelteon (4 mg/mL) oral suspension, which is the subject of ANDA No. 219541 ("MSN's ANDA Product") Compl. ¶1

Functionality and Market Context

  • The accused product is a generic drug for which Defendants seek FDA approval to market for the treatment of nighttime sleep disturbances caused by SMS in children aged 3 to 15 Compl. ¶27 As an ANDA product, it is intended to be bioequivalent to Plaintiff's approved Hetlioz LQ® oral suspension Compl. ¶28 The complaint alleges that the proposed prescribing information (label) for the accused product will be identical or substantially identical in its key instructional sections to the FDA-approved label for Hetlioz LQ®, which forms the basis for the allegations of induced infringement (Compl. ¶¶37; Compl. ¶52; Compl. ¶67; Compl. ¶79). The dosing table presented in the complaint shows weight-based and fixed-dose instructions for pediatric patients. This table, provided in the complaint as an example of the branded drug's label, illustrates the specific instructions for administration that Plaintiff alleges Defendants' generic will also contain Compl. ¶18

IV. Analysis of Infringement Allegations

U.S. Patent No. 10,179,119 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for the treatment of a sleep disorder in a patient with Smith-Magenis Syndrome (SMS), Defendants have filed an ANDA seeking approval to market their generic tasimelteon product for the treatment of nighttime sleep disturbances associated with SMS. ¶27 col. 2:7-9
the method comprising: internally administering to the patient an effective amount of tasimelteon Defendants' proposed prescribing information will allegedly instruct prescribers to administer the accused product, which contains tasimelteon, in an amount effective to treat the condition. ¶38 col. 2:10-12
once daily before bedtime. Defendants' proposed prescribing information will allegedly instruct for once daily administration before bedtime to treat the sleep disturbances. ¶38 col. 6:5-7

U.S. Patent No. 11,266,622 Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for the treatment of a sleep disorder in a patient with Smith-Magenis Syndrome (SMS), Defendants seek approval to market their generic product for the treatment of nighttime sleep disturbances associated with SMS. ¶27 col. 2:11-14
the method comprising: administering to the patient 20 mg of tasimelteon daily. Defendants' proposed prescribing information, by copying the Hetlioz LQ® label, will allegedly instruct the administration of 20 mg of tasimelteon daily for patients weighing more than 28 kg. ¶¶18; ¶36; ¶108 col. 6:4-7

Identified Points of Contention

  • Scope Questions: For the '119 patent, a central question may be the scope of the term "effective amount". While the patent provides examples such as 20 mg, the claim language is broader. Defendants may argue this term is indefinite or does not cover all doses provided in their label.
  • Technical Questions (Induced Infringement): The core of the case for the method patents rests on induced infringement. A primary point of contention will be whether Defendants' proposed product label, which is required by law to be substantially a copy of the Hetlioz LQ® label, does more than merely describe an FDA-approved use and instead contains specific instructions that actively "encourage" or "promote" the performance of the patented methods with the requisite intent for infringement.
  • Evidentiary Questions (Direct Infringement): For the High Purity patents ('977 and '011), the dispute will be factual: does the API in Defendants' ANDA product actually meet the negative limitations of the claims (i.e., contain less than 0.15% of specified impurities)? This will require chemical analysis of Defendants' product during discovery.
  • Invalidity Questions: A significant dispute is foreshadowed regarding the validity of the High Purity patents. The complaint notes that Defendants intend to rely on a Chinese patent application (CN019) as anticipatory prior art Compl. ¶92 The case may turn on whether the court finds that the CN019 reference provides an enabling disclosure for producing tasimelteon with the claimed purity Compl. ¶93

V. Key Claim Terms for Construction

The Term: "effective amount" (from claim 1 of the '119 patent)

  • Context and Importance: This term's construction is critical for determining the scope of infringement of the '119 patent. Its definition will determine which dosages instructed on the accused label fall within the claim. Defendants may argue the term is indefinite under 35 U.S.C. § 112, while Plaintiff will likely argue it is sufficiently defined by the specification.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The plain language of the claim uses the general term "effective amount" without a specific numerical limit, suggesting any amount that achieves the therapeutic result could infringe.
    • Evidence for a Narrower Interpretation: The specification provides specific examples of effective amounts, stating the dose "is between about 5 mg/day and about 100 mg/day," "e.g., between about 20 mg and about 50 mg, e.g., about 20 mg/d" ('119 Patent, col. 6:2-6). A court could potentially limit the term's scope to this disclosed range or to the specific 20 mg example.

The Term: "before bedtime" (from claim 1 of the '119 patent)

  • Context and Importance: Practitioners may focus on this term because the timing of administration is a key element of the claimed method. The accused label allegedly instructs administration "one hour before bedtime" (Compl. ¶36). The dispute will be whether this specific instruction falls within the potentially broader claim language.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: The claim language "before bedtime" is facially broad and could be interpreted to mean any time prior to the patient going to sleep on a given day.
    • Evidence for a Narrower Interpretation: The specification provides more specific timing, stating the administration is "prior to sleep, e.g., between about 0.5 hours and about 1.5 hours prior to sleep, e.g., about 1 hour prior to sleep" '119 Patent, col. 6:5-7 This could be used to argue for a narrower construction limited to this timeframe.

VI. Other Allegations

Indirect Infringement

  • The complaint's primary theory is induced infringement under 35 U.S.C. § 271(b). It is alleged that by filing an ANDA with proposed labeling that copies the instructional language of the Hetlioz LQ® label, Defendants know and intend for prescribers and patients to perform the patented methods of treatment Compl. ¶¶103-104 The complaint also pleads contributory infringement under § 271(c), alleging that the tasimelteon oral suspension is a material part of the invention, is not a staple article of commerce, and has no substantial non-infringing use Compl. ¶105

Willful Infringement

  • The complaint does not include a separate count for willful infringement. However, it requests that the case be declared "exceptional" under 35 U.S.C. § 285 and seeks enhanced damages, which are remedies associated with willful infringement Compl. ¶ Prayer i Compl. ¶ Prayer j The basis for this allegation appears to be Defendants' pre-suit knowledge of the patents, as evidenced by their submission of Paragraph IV certifications Compl. ¶¶24-26

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of induced infringement: will the court determine that Defendants' proposed product label, which under FDA regulations must substantially copy the innovator's label, contains active instructions sufficient to establish the specific intent required to induce infringement of the method-of-use patents, or will it be seen as merely describing an approved indication?
  • A key validity question will be one of prior art enablement: does the cited Chinese patent application (CN019) provide a disclosure sufficient to enable a person of ordinary skill in the art to produce tasimelteon with the purity levels recited in the High Purity patents ('977 and '011), or will the court agree with Plaintiff's assertion that the reference is non-enabling and thus cannot anticipate?
  • The infringement analysis for the '119 patent may turn on a question of claim scope: how will the court construe the term "effective amount"? Will the term be limited to the specific 20 mg dose disclosed in the specification and claimed in the related '622 patent, or will it be given a broader interpretation that could cover all dosing instructions on the accused label?